Layer Slider

Slide background
Slide backgroundSlide thumbnail
Slide backgroundSlide thumbnail
Slide backgroundSlide thumbnail

Slide backgroundTeamTeamTeam
Slide backgroundResearch TextResearch Text
Slide backgroundSlide thumbnail

Slide backgroundCell2Cell2
Slide backgroundVision1
Slide backgroundVideo2Video2

Research

Research

NewsPage

Clinical Support

Latest News

ICON L

Anticancer Effect of Lysine, Proline, Arginine, Ascorbic Acid and Green Tea Extract on Human Renal Adenocarcinoma Line 786-0

M.W. Roomi, V. Ivanov, T. Kalinovsky, A. Niedzwiecki, M. Rath
Oncology Reports 2006; 16(5): 943-947.

Introduction:
Five-year survival is limited to 60% in renal cancer patients at diagnosis. Due to the cancer’s resistance to conventional treatments and associated high morbidity, we investigated the antimetastatic effects of a specific nutrient mixture (NM) containing lysine, proline, arginine, ascorbic acid, and green tea extract on human renal adenocarcinoma cell line 786-0 by measuring: cell proliferation, modulation of MMP-2 and –9 secretion, and cancer cell invasive potential.

Methods:
Human renal cancer cell line 786-0 (ATCC) was grown in RPMI medium in 24-well tissue culture plates. At near confluence, the cells were treated with NM, dissolved in media, and tested at 0, 10, 50, 100, 500, and 1000 mg/ml in triplicate at each dose. Cells were also treated with PMA 200 ng/ml to study enhanced MMP-9 activity. Cell proliferation was evaluated by MTT assay, MMP secretion by gelatinase zymography, and invasion through Matrigel.

Results:
Zymography demonstrated MMP-2 and MMP-9 secretion by uninduced renal cancer cells with enhanced MMP-9 induced by PMA (200 ng/ml) treatment. NM inhibited the secretion of both MMPs in a dose-dependent fashion with virtual total inhibition of MMP-2 at 500-µg/ml concentration and MMP-9 at 100 µg/ml. The invasion of renal cancer cells through Matrigel was totally inhibited (p=0.0001) by NM at 1000 µg/ml concentration.

Conclusion:
Our results support a potential role for the nutrient mixture tested in the treatment of renal cell carcinoma, by inhibition of MMP-2 and MMP-9 secretion and invasion.